Article
IntraLase prepares for $92 million IPO
Irvine, CA-In anticipation of the initial public offering (IPO) of its common stock, IntraLase Corp. has filed a registration statement with the Securities and Exchange Commission.
Related Videos
Anat Loewenstein comments on the recent FDA approval of revakinagene taroretcel-lwey (ENCELTO) for macular telangiectasia type 2 treatment
NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
EnVision Summit 2025: Glaucoma with co-existing ocular co-morbidities
AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
EnVision Summit 2025: Ergonomics in the operating room
EnVision Summit 2025: Complications in glaucoma surgery
AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
50 years in ophthalmology: Glaucoma advancements
AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
50 Years in Ophthalmology: A look at glaucoma treatments
Related Content
